Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|67|2|514-523

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.67, Iss.2, 2018-02, pp. : 514-523

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 505-513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1037-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1037-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

By  

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1127-1135

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 6, 2015-06 ,pp. : 1040-1048

John Wiley & Sons Inc

Access to resources Recommend Favorite